Company shares are trading at $15.75 barely above the 50 day moving average of $14.96 and which is marginally higher than the 200 day moving average of $14.63. The 50 day moving average was up by +5.31% and the 200 day average was up $1.12. (NASDAQ:CNCE) shares saw heavy trading volume with 446K shares changing hands by the end of trading on Tuesday. Overall, volume was up 64.96% over the stocks normal daily volume.
Short traders are more bearish on Concert Pharmaceuticals, Inc. of late if you consider the motion in short interest. The firm realized a rise in short interest of 14.35% as of the latest report on September 29, 2017. Short shares increased from 440,158 to 503,302 over that period. With short interest at 503,302 and short average daily volume at 137,757, the short-interest ratio is 4.0 and the short interest percentage is 0.02% as of September 29.
These funds have shifted positions in (CNCE). As of the end of the quarter Cutler Group LP had disposed of a total of 100 shares trimming its stake by 20.0%. The value of the investment in Concert Pharmaceuticals, Inc. went from $0 to $0 a change of nan% quarter to quarter. Meeder Asset Management Inc reduced its position by shedding 129 shares a decrease of 36.1%. Meeder Asset Management Inc now holds 228 shares valued at $3,000. The value of the position overall is down by 40.0%.
Rockefeller Financial Services Inc cut its investment by selling 756 shares a decrease of 7.3% from 06/30/2017 to 09/30/2017. Rockefeller Financial Services Inc owns 9,533 shares with a value of $141,000. The total value of its holdings decreased 2.1%. As of quarter end Ingalls & Snyder LLC had bought 153,062 shares growing its position 14.5%. The value in dollars increased from $14,731,000 to $17,834,000 a change of $3,103,000 for the reporting period.
On July 24, 2017 H.C. Wainwright began coverage of the stock by announcing an initial rating of “Buy”.
As of the last earnings report the EPS was $-2.22 and is expected to be $-2.18 for the current year with 22,687,000 shares outstanding. Next quarter’s EPS is forecasted to be $-0.73 and the next full year EPS is projected to be $-2.44.
Concert Pharmaceuticals, Inc., launched on April 12, 2006, is a clinical-stage biopharmaceutical company. The Company is involved in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Business’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386..